[HTML][HTML] Targeting TNF-α for COVID-19: recent advanced and controversies
Y Guo, K Hu, Y Li, C Lu, K Ling, C Cai… - Frontiers in public …, 2022 - frontiersin.org
… understanding of coronavirus disease 2019 (COVID-19) … characterized by increased tumor
necrosis factor α (TNF-α), interleukin (… of targeting the TNF-α pathway in COVID-19 treatment. …
necrosis factor α (TNF-α), interleukin (… of targeting the TNF-α pathway in COVID-19 treatment. …
[HTML][HTML] Prospective roles of tumor necrosis factor-alpha (TNF-α) in COVID-19: prognosis, therapeutic and management
Z Mohd Zawawi, J Kalyanasundram… - International journal of …, 2023 - mdpi.com
… -19 morbidity and mortality. In addition, this review … of TNF-α as a biomarker for the prognosis
of severe COVID-19 and its related complications and as a molecular target for anti-TNF-α …
of severe COVID-19 and its related complications and as a molecular target for anti-TNF-α …
TNFα inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis
XY Chen, BX Yan, XY Man - Therapeutic Advances in …, 2020 - journals.sagepub.com
… (TEN) and COVID-19, we hypothesize that the application of etanercept, an inhibitor of
TNFα, could attenuate disease progression in severe group COVID-19 patients by suppressing …
TNFα, could attenuate disease progression in severe group COVID-19 patients by suppressing …
Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept
PM Duret, E Sebbag, A Mallick, S Gravier… - Annals of the …, 2020 - ard.bmj.com
… over the course of COVID-19. We report the case of a recovery from COVID-19 in a 60- year-
… tumour necrosis factor- alpha (TNF-α) inhibitor (the soluble TNF receptor: etanercept 50 mg, …
… tumour necrosis factor- alpha (TNF-α) inhibitor (the soluble TNF receptor: etanercept 50 mg, …
Association of TNF-α G-308 a Promoter Polymorphism with the Course and Outcome of COVID-19 Patients
A Saleh, A Sultan, MA Elashry, A Farag… - Immunological …, 2022 - Taylor & Francis
… and severe COVID-19 complications and the association of A allele with high TNF-α production,
… to assess the validity of TNF-α G-308 A promoter polymorphism in COVID-19 patients. …
… to assess the validity of TNF-α G-308 A promoter polymorphism in COVID-19 patients. …
[HTML][HTML] IFN-γ and TNF-α drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 lungs and inflammatory diseases with tissue inflammation
… between inflammatory diseases with COVID-19, we meta-analyzed and integrated tissue-level
single-cell profiles from five inflammatory diseases and COVID-19. We created an …
single-cell profiles from five inflammatory diseases and COVID-19. We created an …
CD4+ T-Cell Dysfunction in Severe COVID-19 Disease Is Tumor Necrosis Factor-α/Tumor Necrosis Factor Receptor 1–Dependent
… higher TNF-α … COVID-19 is TNF-α/TNF receptor 1–dependent through immune mechanisms
that may contribute to lymphopenia. TNF-α blockade may be beneficial in severe COVID-19. …
that may contribute to lymphopenia. TNF-α blockade may be beneficial in severe COVID-19. …
[HTML][HTML] The second decade of anti-TNF-a therapy in clinical practice: New lessons and future directions in the COVID-19 era
… The current COVID-19 pandemic revealed also unexpected … anti-TNF-α agents [17]; anti-TNF-α
use protects against severe COVID-19 infection and hospitalization due to COVID-19 and …
use protects against severe COVID-19 infection and hospitalization due to COVID-19 and …
Anti-TNF-α agents in inflammatory bowel disease and course of COVID-19
A Tursi, LM Vetrone, A Papa - Inflammatory Bowel Diseases, 2020 - academic.oup.com
… patients with IBD and COVID-19 spontaneously inserted by … of COVID-19 is lower in patients
in treatment with anti-TNF-α … patients with COVID-19 in treatment with anti-TNF-α needed …
in treatment with anti-TNF-α … patients with COVID-19 in treatment with anti-TNF-α needed …
Lower serologic response to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases treated with anti-TNFα
…, MH Pauker, A Friedenberg, A Levy-Barda, A Segal… - Gastroenterology, 2022 - Elsevier
… anti–tumor necrosis factor α … against COVID-19 started in Israel on December 19, 2020, with
mRNA-based … for the efficacy and safety of the COVID-19 BNT162b2 vaccine in patients with …
mRNA-based … for the efficacy and safety of the COVID-19 BNT162b2 vaccine in patients with …
相关搜索
- covid 19 tnf alpha inhibitor etanercept
- course of covid 19 tnf antagonists
- covid 19 cytokine storm
- covid 19 patients
- covid 19 inflammatory bowel disease
- anti-tnf α agents
- severe covid 19
- covid 19 rheumatic diseases
- covid 19 pandemic
- covid 19 clinical course
- covid 19 sars cov 2
- tnf α outcome of covid 19
- covid 19 pneumonia factor α
- covid 19 tumor necrosis factor alpha
- covid 19 anti-tnf therapy
- advances in covid 19